# Oral GABA treatment as a novel and safe therapy to ameliorate Sjögren’s syndrome

> **NIH NIH R21** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2020 · $234,000

## Abstract

PROJECT SUMMARY
Sjögren's syndrome is a chronic autoimmune disease characterized by immune cell infiltration into exocrine
glands, particularly the salivary and lacrimal glands which leads to severe loss of secretory function and
consequent oral and ocular health problems. The disease affects four million Americans with over 90% of those
affected being female. Currently, there are no effective therapies to inhibit or reverse the course of Sjögren's
syndrome. Treatments are limited to ameliorating the disease's symptoms and may be needed life-long.
Accordingly, there is a need to develop new therapeutic approaches for Sjögren's syndrome that can safely
control the underlying inflammatory responses. Recently, it has become appreciated that T cells and antigen-
presenting cells express gamma-amino-butyric acid receptors (GABA-Rs) and that the activation of these
receptors has several desirable effects for inhibiting inflammation, including 1) inhibiting Th17 and Th1
responses, 2) reducing APC proinflammatory activity, and 3) promoting CD4+ and CD8+ Treg responses. These
immunoregulatory actions have enabled oral GABA administration to reverse chronic T cell-mediated
autoimmune diseases such as type 1 diabetes (T1D), multiple sclerosis (MS), and rheumatoid arthritis after the
onset of clinical symptoms in mouse models of these disorders. Human T cells also express GABA-Rs, and
GABA has been shown to regulate them in a similar fashion. GABA's immunomodulatory effects are modest, do
not cause immuno-depletion, and GABA is safe for human consumption. Clinical trials of oral GABA for T1D are
currently underway. Given the ability of GABA-R agonists to reverse disease in different chronic autoimmune
disease models, each of which have different etiologies and occur in mice with different genetic backgrounds, it
is reasonable to posit that oral GABA treatment could provide a novel and safe therapy to help ameliorate
Sjögren's syndrome. This proposal will test the ability of oral GABA therapy to ameliorate disease in two different
mouse models of Sjögren's syndrome when given at early and advanced stages of the disease. A proof-of-
principle could lead to rapid clinical translation due to the safety of GABA consumption.

## Key facts

- **NIH application ID:** 9948637
- **Project number:** 5R21DE029020-02
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** DANIEL KAUFMAN
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $234,000
- **Award type:** 5
- **Project period:** 2019-07-01 → 2021-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9948637

## Citation

> US National Institutes of Health, RePORTER application 9948637, Oral GABA treatment as a novel and safe therapy to ameliorate Sjögren’s syndrome (5R21DE029020-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9948637. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*